161650-01-7 Usage
Uses
Used in Pharmaceutical Industry:
(PRO30,TYR32,LEU34)-NEUROPEPTIDE Y (28-36) is used as a therapeutic agent for the treatment of obesity and eating disorders due to its role in regulating appetite and energy balance. It modulates the hypothalamic pathways involved in appetite control, potentially leading to reduced food intake and weight loss.
Used in Neurological Applications:
In the field of neurology, (PRO30,TYR32,LEU34)-NEUROPEPTIDE Y (28-36) is used as a potential treatment for anxiety disorders. Its involvement in stress responses and modulation of neurotransmitters suggests that it may help alleviate anxiety symptoms and improve overall mental well-being.
Used in Cardiovascular Research:
(PRO30,TYR32,LEU34)-NEUROPEPTIDE Y (28-36) is utilized in cardiovascular research as a potential therapeutic target for the modulation of cardiovascular function. Its role in the regulation of blood pressure, heart rate, and vascular tone makes it a promising candidate for the development of drugs targeting cardiovascular diseases.
Used in Inflammation Management:
In the field of inflammation, (PRO30,TYR32,LEU34)-NEUROPEPTIDE Y (28-36) is used as a potential anti-inflammatory agent. Its involvement in the modulation of inflammatory processes suggests that it may help reduce inflammation and alleviate symptoms associated with inflammatory disorders.
Check Digit Verification of cas no
The CAS Registry Mumber 161650-01-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,1,6,5 and 0 respectively; the second part has 2 digits, 0 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 161650-01:
(8*1)+(7*6)+(6*1)+(5*6)+(4*5)+(3*0)+(2*0)+(1*1)=107
107 % 10 = 7
So 161650-01-7 is a valid CAS Registry Number.
161650-01-7Relevant academic research and scientific papers
Novel Modified Carboxy Terminal Fragments of Neutropeptide Y with High Affinity for Y2-Type Receptors and Potent Functional Antagonism at a Y1-Type Receptor
Leban, Johann J.,Heyer, Dennis,Landavazo, Antonio,Matthews, Jessica,Aulabaugh, Ann,Daniels, Alejandro J.
, p. 1150 - 1157 (2007/10/02)
Peptide analogs of neuropeptide Y (NPY) with a Tyr-32 and Leu-34 replacement resulted in the decapeptide TyrIleAsnLeuIleTyrArgLeuArgTyr-NH2 (9; Table 1) and a 3700-fold improvement in affinity at Y2 (rat brain; IC50 = 8.2 +/- 3 nM) receptors when compared to the native NPY(27-36) C-terminal fragment.In addition, compound 9 was an agonist at Y1 (human erythroleukemia (HEL) cell; ED50 = 8.8 +/- 0.5 nM) receptors with potency comparable to that of NPY(1-36) (ED50 = 5 nM).Molecular dynamics and 1H-NMR were used to propose a solution structure of decapeptide 9 and for subsequent analog design.The replacement of Leu with Pro at position 4 of decapeptide 9 afforded an antagonist of NPY in HEL cells (18, TyrIleAsnProIleTyrArgLeuArgTyr-NH2; IC50 = 100 +/- 5 nM).Deletion of the N-terminal tyrosine of 18 resulted in a 10-fold improvement in antagonistic activity with a parallel 4-fold decrease in Y2 affinity.This potent antagonist may provide further insight into the physiological role(s) for NPY in the mammalian and peripheral nervous system.
